GeoVax Labs to update its HIV/AIDS vaccine status at World Vaccine Conference

Apr 8 2011

Harriet Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), will provide an update on the status of the Company's therapeutic and preventative HIV vaccines at the 2011 World Vaccine Conference at the Gaylord National Hotel and Convention Center in Washington DC on Thursday, April 14.  Dr. Robinson's invited talk, which will run from 11:30 – 11:50 a.m., will cover the topic of recombinant viruses as vaccines. The talk will be followed by a Q&A session at 12:30 pm.

GeoVax has a multi-protein clade B HIV/AIDS vaccine in an open-label Phase 1/2 therapeutic trial and in a double-blinded, 300-participant Phase 2a preventative trial.  The preventative trial is being conducted and supported by the US HIV Vaccine Trials Network (HVTN). The vaccine was developed in Dr. Robinson's former laboratory at the Emory Vaccine Center in collaboration with Dr. Bernard Moss's laboratory at the US National Institutes of Health and researchers at the US Centers for Disease Control and Prevention.  Recently, the Company announced a 70% prevention rate in a non-human primate study using their GM-CSF co-expressing  vaccine.  This represents the highest successful prevention rate ever achieved in such a non-human model with a preventative vaccine for HIV.

Dr. Robinson, formerly Asa Griggs Candler Professor of Microbiology and Immunology at Emory University and Chief of the Division of Microbiology and Immunology at the Yerkes National Primate Research Center, is internationally recognized for her work on HIV/AIDS vaccines, her pioneering studies on the use of recombinant DNA for vaccination and her seminal studies on insertional mutagenesis and oncogene transduction in retroviral induced cancers. She received her Ph.D. from the Massachusetts Institute of Technology and her postdoctoral training at the Virus Laboratory, University of California Berkeley. Dr. Robinson is active on several editorial boards and has consulted for the US NIH, the US Food and Drug Administration, the World Health Organization, and the Gates Foundation.

The annual World Vaccine Conference, which attracted over 485 delegates in 2010, provides attendees with the opportunity to hear from North America's leading governmental stakeholders, business leaders and scientific stakeholders as they continue to enhance the scientific and strategic innovation behind a burgeoning vaccine industry.